Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Respiratory medicine
- Publicado em
- 16 jul 2025
- Citações
- 34
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
Lorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, Maelenn Gouillou, Muhammad Hammad Ali, Samreen Amjad, Farees Kamal, Amanzhan Abubakirov, Elisa Ardizzoni, Elisabeth Baudin et al.
Descritores MeSH
- Diarylquinolines
- Antitubercular Agents
- Clofazimine
- Nitroimidazoles
- Oxazoles
- Tuberculosis, Pulmonary
- Tuberculosis, Multidrug-Resistant
- Linezolid
- Middle Aged
- Treatment Outcome
Veja também
Estudos relacionados
- A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
- Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)
- Executive Summary: Clinical Practice Guidelines on the Management of Resistant Tuberculosis of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)
- A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis